{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 102 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'have recently started nintedanib 150 mg BID', 'and have started by the day of randomization', 'must be on nintedanib 150 mg BID a minimum', 'of 10 days by the first day of pulmonary', 'rehabilitation.\"', 'Rationale for change', 'Updated to improve recruiting opportunities.', 'Section to be changed', '5.1.2.5', 'Description of change', 'Rationale for change', 'Administrative change.', 'Section to be changed', '5.2.6.1', 'Description of change', 'Added Gastrointestinal perforation', 'Rationale for change', 'To align with program AESIs', 'Section to be changed', '5.2.6.2', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 103 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'Description of change', 'Changed \"fax\" to \"submit\"', 'Rationale for change', 'Administrative', 'Section to be changed', '6.2.1', 'Description of change', 'Changed Visit 0 and Visit 1 to reflect', 'update to INC 1-\"for up to 30 months\"', 'and added \" Patients who have recently', 'started nintedanib 150 mg BID and have', 'started by the day of randomization', 'must be on nintedanib 150 mg BID a', 'minimum of 10 days by the first day of', 'pulmonary rehabilitation.\"', 'Rationale for change', 'Updated to improve recruiting opportunities.', 'Section to be changed', '6.2.2', 'Description of change', 'Update \"4 weeks\" to \"6 weeks\"', 'Rationale for change', 'To increase the window to schedule PR.', 'Section to be changed', '7.1', 'Description of change', 'Updated \" currently taking nintedanib at a dose', 'of 150 mg bid for not less than 3 months or', 'more than 30 months\" to \"currently treated', 'with nintedanib at a dose of 150 mg bid for up', 'to 30 months\"', 'Rationale for change', 'Updated to improve recruiting opportunities.', 'Section to be changed', '10.7', 'Description of change', 'Updated FVC to 45%', 'Rationale for change', 'Updated to improve recruiting opportunities', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer', 'Ingelheim', 'APPROVAL / SIGNATURE PAGE', 'Document Number: c19558808', 'Technical Version Number:6.0', 'Document Name: clinical-trial-protocol-version-3.0', 'Title: Study of Pulmonary Rehabilitation In Nintedanib Treated Patients with IPF:', 'Improvements in Activity, Exercise Endurance Time, and QoL', 'Signatures (obtained electronically)', 'Meaning of Signature', 'Signed by', 'Date Signed', 'Author-Clinical Trial Leader', '16 Dec 2019 15:30 CET', 'Author-Trial Statistician', '16 Dec 2019 16:42 CET', 'Approval-Medical', '16 Dec 2019 23:10 CET', 'Approval-Therapeutic Area', '16 Dec 2019 23:20 CET', 'Approval-Team Member Medicine', '18 Dec 2019 14:02 CET', 'Verification-Paper Signature', '18 Dec 2019 14:10 CET', 'Completion']\n\n###\n\n", "completion": "END"}